These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16565232)

  • 21. Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    McQueen MJ; Gerstein HC; Pogue J; Mann JF; Yusuf S
    Am J Kidney Dis; 2006 Dec; 48(6):889-96. PubMed ID: 17162143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients.
    Kato T; Horio T; Tomiyama M; Kamide K; Nakamura S; Yoshihara F; Nakata H; Nakahama H; Kawano Y
    Nephrol Dial Transplant; 2007 Mar; 22(3):911-6. PubMed ID: 17142262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.
    Ibsen H; Olsen MH; Wachtell K; Borch-Johnsen K; Lindholm LH; Mogensen CE
    J Nephrol; 2008; 21(4):566-9. PubMed ID: 18651547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice.
    Volpe M
    Int J Clin Pract; 2008 Jan; 62(1):97-108. PubMed ID: 17971155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Microalbuminuria in diabetes: setting the points for treatment].
    Lehnert H; Klose S; Lobmann R; Zehnder D
    MMW Fortschr Med; 2006 May; 148(21):28-30, 33; quiz 34. PubMed ID: 16796185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Microalbuminuria].
    Olsen MH; Ibsen H; Mogensen CE
    Ugeskr Laeger; 2009 Jun; 171(25):2097-100. PubMed ID: 19671389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microalbuminuria in primary hypertension: a guide to optimal patient management?
    Viazzi F; Cappadona F; Pontremoli R
    J Nephrol; 2016 Dec; 29(6):747-753. PubMed ID: 27417557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing vascular risk in hypertension with a focus on microalbuminuria: attitude and practices.
    Wu AY; Low LP
    Singapore Med J; 2009 Oct; 50(10):976-81. PubMed ID: 19907888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance and microalbuminuria are associated with microvascular disease in patients with cirrhosis.
    Krok KL; Milwalla F; Maheshwari A; Rankin R; Thuluvath PJ
    Liver Transpl; 2009 Sep; 15(9):1036-42. PubMed ID: 19718631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of microalbuminuria in achieving blood pressure goals.
    Duka I; Bakris G
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):457-63. PubMed ID: 18695385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for development of microalbuminuria in diabetic and nondiabetic normoalbuminuric hypertensives with high or very high cardiovascular risk - a twelve-month follow-up study.
    Cotter J; Oliveira P; Cunha P; Polónia J
    Nephron Clin Pract; 2009; 113(1):c8-15. PubMed ID: 19590230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure load, vascular permeability and target organ damage in primary hypertension.
    Falqui V; Viazzi F; Leoncini G; Ratto E; Parodi A; Conti N; Tomolillo C; Deferrari G; Pontremoli R
    J Nephrol; 2007; 20 Suppl 12():S63-7. PubMed ID: 18050146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?
    de Jong PE; Gansevoort RT; Bakker SJ
    J Nephrol; 2007; 20(4):375-80. PubMed ID: 17879201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the use of urinary albumin as marker of kidney involvement in unselected populations.
    McQueen MJ
    Scand J Clin Lab Invest Suppl; 2008; 241():52-6. PubMed ID: 18569965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Microalbuminuria as a prognostic marker of cardiovascular diseases].
    Lisowska-Myjak B
    Pol Merkur Lekarski; 1997 Jul; 3(13):28-9. PubMed ID: 9432297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S; Lewis JB
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.